Document Detail

The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis.
MedLine Citation:
PMID:  18048383     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The use of adjuvant carboplatin in the management of stage I seminoma of the testis has been limited by the lack of long-term data. In this study, we address this issue for the first time. PATIENTS AND METHODS: Data on 199 patients treated with single-agent carboplatin for stage I seminoma of the testis were prospectively collected. Overall mortality, deaths from circulatory disease and the incidence of second cancers were compared with expected values derived from the UK general population. RESULTS: The median follow-up for the cohort was 9.0 years (range 0.1-20.1). There has been no excess in overall mortality [standardised mortality ratio (SMR) 0.89; 95% CI 0.36-1.83], death from circulatory diseases (SMR 1.44; 95% CI 0.39-3.69) or the incidence of second nontestis cancers (standardised incidence ratio 0.96; 95% CI 0.26-2.45) in this group of patients. These findings also applied to specific follow-up periods of >5 or 10 years. Specifically, neither haematological nor solid nontestis tumours occurred in excess. There was an increase in the long-term development of contralateral testis cancers. CONCLUSIONS: This study addresses some of the concerns surrounding the long-term safety of single-agent carboplatin. It also helps in planning long-term follow-up for patients receiving this form of treatment.
T Powles; D Robinson; J Shamash; H Moller; N Tranter; T Oliver
Related Documents :
22552243 - Editorial: the role of compassion in the practice of evidence-based medicine.
18304693 - Acutely decompensated heart failure in a county emergency department: a double-blind ra...
17320583 - Video-assisted thoracic surgery does not reduce the incidence of postoperative atrial f...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-11-28
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  19     ISSN:  1569-8041     ISO Abbreviation:  Ann. Oncol.     Publication Date:  2008 Mar 
Date Detail:
Created Date:  2008-02-28     Completed Date:  2008-03-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  443-7     Citation Subset:  IM    
Department of Medical Oncology, St Bartholomew's Hospital, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use
Carboplatin / therapeutic use*
Carcinoma, Small Cell / epidemiology
Cause of Death
Chemotherapy, Adjuvant
Cohort Studies
Follow-Up Studies
Great Britain / epidemiology
Hematologic Neoplasms / epidemiology
Hodgkin Disease / epidemiology
Lung Neoplasms / epidemiology
Lymphatic Metastasis
Meningeal Neoplasms / epidemiology
Meningioma / epidemiology
Middle Aged
Neoplasm Staging
Neoplasms, Second Primary / epidemiology*
Seminoma / drug therapy*,  mortality*,  pathology,  secondary
Survival Analysis
Testicular Neoplasms / drug therapy*,  mortality,  pathology
Treatment Outcome
Tumor Markers, Biological / analysis
Reg. No./Substance:
0/Antineoplastic Agents; 0/Tumor Markers, Biological; 41575-94-4/Carboplatin
Comment In:
Ann Oncol. 2008 Mar;19(3):407-8   [PMID:  18227108 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma.
Next Document:  Resveratrol-induced apoptosis depends on the lipid kinase activity of Vps34 and on the formation of ...